Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Bristol Myers Squibb to cut 2,200 jobs as part of $1.5bn cost-savings drive

(Sharecast News) - US drugmaker Bristol Myers Squibb on Thursday announced plans to cut its workforce by 6% as part of a $1.5bn cost-savings programme, as it reported better-than-expected results for the first quarter. The company said it was launching a "Strategic Productivity Initiative" to deliver the cost savings, of which the majority will be reinvested to fund innovation and drive growth.

The initiative includes plans to lay off 2,200 employees this year (from its global headcount of 34,000), reduce management layers, "rationalise" its pipeline, consolidate sites and cut third-party spend.

The news came as BMS delivered net revenues of $11.9bn for the first three months of 2024, up from $11.3bn in 2023 and ahead of the $11.5bn consensus forecast.

However, losses per share widened significantly to $5.89 from a profit of $1.07 a share a year earlier, mainly as a result of a $12.1bn one-off non-tax-deductible charge for the acquisition of Karuna, which completed in March.

As a result of recent deals - which also included the completion of the RayzeBio acquisition February - BMS is now guiding to adjusted EPS of $0.40-0.70 this year, considerably down from the February guidance of $7.10-7.40.

The new guidance includes a $6.73-a-share negative impact from so-called acquired in-process research and development (or IPR&D) as a result of recent closed transactions.

"We had a good start to 2024, with revenue growth, important advances in our pipeline and the closure of several strategically important transactions," said Christopher Boerner, chair and chief executive officer.

"Our focus remains on strengthening the company's long-term growth profile. As a part of our continued evolution, we're executing a strategic productivity initiative that will allow us to be more agile, drive efficiency across the company, and prioritize investing in opportunities where we see the greatest potential to get the most promising medicines to patients as quickly as possible."

The stock was down 8% at $45.05 just before midday in New York.

Share this article

Related Sharecast Articles

RBC Capital lifts Centrica to 'outperform', shares rally
(Sharecast News) - RBC Capital Markets upgraded Centrica on Friday to 'outperform' from 'sector perform' and lifted the price target to 170p from 145p.
Jefferies reiterates 'buy' on National Grid, trims price target
(Sharecast News) - Jefferies trimmed its price target on National Grid on Friday as it reiterated its 'buy' rating on the energy infrastructure firm.
JPMorgan reiterates 'overweight' on Whitbread
(Sharecast News) - JPMorgan Cazenove reiterated its 'overweight' rating on Whitbread on Friday as it said it continues to be one of its key convictions, and sees the recent pullback - the shares are down 20% year-to-date - as "an opportunity to revisit the story".
Short-lived sunny spell helps boost UK supermarkets
(Sharecast News) - UK supermarket sales pushed higher in May, industry data showed on Friday, boosted by a brief spell of warmer weather.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.